A Real-world Study of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: One-year Follow up Results (P6-1.004)

作者
Mengcui Gui,Bitao Bu,Hongyu Zhou,Wei Li,Tao Jin,Dan He
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:106 (11_Supplement_1)
标识
DOI:10.1212/wnl.0000000000215739
摘要

Objective This study aims to evaluate the efficacy and safety of inebilizumab in Chinese patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) through multicenter and large-sample data. Background Inebilizumab is a humanized anti-CD19+ B-cell-depleting agent for the treatment of adult NMOSD patients with AQP4-IgG positivity. It has been marketed in China for about 3 years. However, there is still a lack of multicenter and large-sample data to validate its efficacy and safety in the real-world setting of China. Design/Methods We conducted a real-world study in five centers in the central and western regions of China, and prospectively collected all patients who received inebilizumab treatment from March 2023 to June 2025. We analyzed the disease relapse status of patients, as well as the dynamic changes in the Expanded Disability Status Scale (EDSS) scores and CD19+ B lymphocyte counts. Adverse events were recorded too. Results The study included 138 AQP4-IgG-positive NMOSD patients (86.2% female, mean age 44.8±13.9 years) with a median follow-up of 12.5 months (range 0.4–25.4 months). Only 5 patients relapsed during follow-up. Annualized relapse rate(ARR) decreased from 1.10 before treatment to 0.04. Three patients were lost to follow-up due to relapse and medication change. EDSS mean scores significantly decreased from a baseline of 3.25 to 2.53 at six month and 2.0 at 12 months (p < 0.001). CD19+ B lymphocyte counts also dropped from 268.01/μl to 4.59/μl at six months and 16.69/μl at 12 months (p < 0.001). Serum immunoglobulin levels decreased, but most patients maintained IgG levels above 5g/L. Conclusions The large-sample real-world data from China show that inebilizumab significantly reduces the relapse rate and EDSS scores in AQP4-IgG-positive NMOSD patients with no serious adverse reactions reported. This indicates inebilizumab is an effective and safe treatment option for NMOSD patients in real-world setting. Longer follow-up data to be gathered. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: The institution of Ms. Gui has received research support from Beijing Huikang Charity Foundation . Dr. Bu has nothing to disclose. Prof. Zhou has nothing to disclose. Dr. Li has nothing to disclose. Prof. Jin has nothing to disclose. Dr. He has nothing to disclose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
散装洋芋发布了新的文献求助10
1秒前
NexusExplorer的应助被橙子采纳,获得10
1秒前
蜜糖果仁完成签到,获得积分10
2秒前
zyh666完成签到,获得积分10
2秒前
甜美寻双给甜美寻双的求助进行了留言
2秒前
linxi完成签到,获得积分10
2秒前
heshicong完成签到,获得积分10
3秒前
3秒前
小王院士完成签到,获得积分10
3秒前
4秒前
5秒前
5秒前
炸薯条发布了新的文献求助10
6秒前
糊涂的向秋完成签到,获得积分10
6秒前
赘婿的应助被bow采纳,获得10
6秒前
369ninja的应助被fyl采纳,获得10
7秒前
璐璐发布了新的文献求助10
7秒前
扶桑完成签到,获得积分10
8秒前
9秒前
9秒前
111完成签到,获得积分10
10秒前
风吹麦浪的应助被believe采纳,获得10
11秒前
秋风的应助被任性的皮卡丘采纳,获得10
11秒前
yiyi发布了新的文献求助10
11秒前
12秒前
12秒前
12秒前
13秒前
赘婿的应助被朴素的藏今采纳,获得10
13秒前
Caclos完成签到 ,获得积分10
13秒前
13秒前
wanci的应助被olivia采纳,获得10
13秒前
1111111111完成签到,获得积分10
14秒前
万诚信完成签到,获得积分10
15秒前
liangyu发布了新的文献求助10
15秒前
16秒前
glz007发布了新的文献求助10
16秒前
负责的代亦完成签到,获得积分20
17秒前
19秒前
给苏打饼干扎眼完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527